Welcome to our dedicated page for Zai Lab SEC filings (Ticker: ZLAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Zai Lab’s latest 10-K means wading through hundreds of pages on oncology trial endpoints, milestone royalties, and cross-border licensing terms. Finding when executives file Form 4s before a key Phase III read-out can be equally demanding. Stock Titan’s AI-powered SEC dashboard turns that complexity into clarity.
Our platform monitors every Zai Lab quarterly earnings report 10-Q filing, Zai Lab annual report 10-K simplified, and Zai Lab 8-K material events explained the moment they hit EDGAR. Instantly see cash-runway updates, trial spend, and collaboration revenue without scrolling line-by-line. Need fast answers to “Zai Lab SEC filings explained simply� or “understanding Zai Lab SEC documents with AI�? The summary panel delivers plain-English context, key metrics, and citation links in seconds.
Stay alerted to Zai Lab insider trading Form 4 transactions. We surface Zai Lab Form 4 insider transactions real-time, flagging option exercises and open-market buys so you can assess sentiment before headlines hit. The proxy center pairs Zai Lab proxy statement executive compensation data with visual charts that benchmark R&D bonuses and equity grants against biotech peers.
- AI snapshots of pipeline milestones hidden in 10-Qs
- Side-by-side earnings trend graphs for rapid Zai Lab earnings report filing analysis
- One-click downloads of every exhibit—agreements, trial protocols, risk factors
Whether you’re gauging dilution risk, tracking Zai Lab executive stock transactions Form 4, or reviewing disclosure notes on immunology assets, Stock Titan provides the complete, continuously updated repository—decoded for actionable insight.
Zai Lab Limited (NASDAQ: ZLAB) filed a Form 144 indicating that insider Ying Du plans to sell 7,072 American Depositary Shares (ADS) on 02 July 2025 through Fidelity Brokerage Services. The proposed transaction is valued at US$249,143.73, representing roughly 0.0015 % of the company’s 486.9 million ADS outstanding, and stems from the vesting of restricted stock on 01 July 2025.
The filing also discloses that the same insider has already sold 235,729 ADS between 02 April 2025 and 30 June 2025, generating an estimated US$7.1 million in gross proceeds. These prior sales were executed in eight tranches ranging from 2,945�50,000 ADS each.
Although the absolute dollar value of the individual sale is modest relative to Zai Lab’s market capitalization, the cumulative selling pattern may be interpreted by some investors as a signal of insider profit-taking. No new operational, earnings or strategic information is provided in this filing; the document is strictly a regulatory notice satisfying Rule 144 requirements.
Zai Lab (NASDAQ:ZLAB) filed a Form 4 revealing that Chief Legal Officer Edmondson Frazor Titus III’s 14,600 RSUs vested on 25 Jun 2025, converting into the same number of ADSs.
To cover withholding taxes, he sold 5,877 ADSs on 26 Jun 2025 at $36.132 (� $213 k), coded “S�. Post-transaction, his direct stake stands at 44,975 ADSs, each ADS representing ten ordinary shares.
The sale, while automatic under a Rule 10b5-1 plan, equals roughly 12 % of his pre-sale position, crossing the 5 % materiality threshold and offering investors a governance data-point rather than a directional signal.
Key Form 4 details for Zai Lab Ltd (ZLAB): On 25 June 2025, Chairperson & CEO Ying Du received 58,800 American Depositary Shares (ADS) upon the vesting of previously granted Restricted Share Units (RSUs). Each ADS represents ten ordinary shares. The conversion was reported under transaction code “M,� indicating a delivery of shares without cash consideration.
On 26 June 2025 the executive executed an automatic sale (code “S�) of 23,669 ADS at US $36.132 per ADS to satisfy tax-withholding obligations triggered by the vesting event. After both transactions, Du’s direct beneficial ownership stands at 514,982 ADS.
Net effect: the CEO’s holdings increased by 35,131 ADS relative to the amount immediately prior to the RSU vesting, reinforcing management’s equity alignment while acknowledging routine tax-related disposals. No derivative positions remain in connection with this RSU tranche.
The RSUs follow a four-year vesting schedule that began on 25 June 2023; future anniversaries may lead to similar withhold-to-cover sales. Investors typically view net ownership increases as a positive governance signal, although periodic sales could add modest near-term share supply.
Zai Lab CFO Chen Yajing reported multiple transactions on Form 4 involving American Depositary Shares (ADS) on June 25-26, 2025:
- Acquired 6,250 ADSs through the vesting of Restricted Share Units (RSUs) on June 25
- Subsequently sold 2,675 ADSs at $36.132 per share on June 26 for tax coverage
- Following these transactions, directly owns 21,004 ADSs
The RSUs were granted under a four-year vesting schedule beginning June 25, 2023, with equal annual installments. Each ADS represents ten ordinary shares of the company. The automatic sale of shares was specifically conducted to cover tax obligations from the RSU vesting. The transactions were reported through an attorney-in-fact on June 27, 2025.
Form 144 Notice filed by Zai Lab officer Frazor T. Edmondson for the proposed sale of 5,877 American Depositary Shares with an aggregate market value of $212,344.83 on NASDAQ, planned for June 26, 2025.
Key details of the transaction:
- Shares were acquired through restricted stock vesting on June 25, 2025 as compensation
- Sale is being executed through Fidelity Brokerage Services LLC
- Purpose includes covering tax obligations from vested equity award distribution
Recent trading history shows Edmondson sold 6,243 shares in April 2025 for total proceeds of $218,867.09. The filing confirms no knowledge of material adverse non-public information regarding Zai Lab's operations. Total shares outstanding: 486,853,250.
Zai Lab executive Yajing Chen filed Form 144 indicating intent to sell 2,675 American Depositary Shares with an aggregate market value of $96,651.76. The sale is scheduled for June 26, 2025, through Fidelity Brokerage Services on NASDAQ.
The shares were acquired on June 25, 2025, through restricted stock vesting as part of compensation. The filing notes that the sale is partially intended to cover tax obligations from the vested equity award distribution.
Previous trading activity by Chen in the past 3 months includes:
- June 2, 2025: Sold 9,618 shares for $288,540.00
- April 4, 2025: Sold 924 shares for $30,592.25
- April 2, 2025: Sold 5,280 shares for $189,521.38
The company has approximately 486.85 million shares outstanding. The filing was signed by Wade Moss as a representative of Fidelity Brokerage Services, acting as attorney-in-fact for Chen.
Zai Lab Director and Officer Ying Du filed Form 144 indicating a proposed sale of 23,669 American Depositary Shares with an aggregate market value of $855,196.47 through Fidelity Brokerage Services. The shares were acquired through restricted stock vesting on June 25, 2025, as part of compensation.
Notable recent trading activity by Du includes:
- Multiple large sales in May 2025 totaling 196,389 shares with combined proceeds of $5.68 million
- Two smaller sales in April 2025 totaling 8,753 shares for $305,978
The filing indicates the sale is partially intended to cover tax obligations from vested equity awards. Du has certified no knowledge of undisclosed material adverse information regarding Zai Lab's operations. The company has 486.85 million shares outstanding, and the proposed sale represents approximately 0.005% of total shares.
Peter Wirth, Director at Zai Lab (ZLAB), received a grant of 10,831 American Depositary Shares (ADS) on June 18, 2025. Key details of the transaction:
- Transaction Type: Acquisition of restricted shares
- Purchase Price: $0 (granted as compensation)
- Vesting Schedule: Full vesting on June 18, 2026, contingent on continued board service
- Post-Transaction Holdings: 393,750 ADSs held directly
Each ADS represents ten ordinary shares of Zai Lab. The shares were granted as part of director compensation and are subject to a one-year vesting period. This Form 4 filing was submitted by Bruce Blefeld as attorney-in-fact on June 23, 2025.
FAQ
What is the current stock price of Zai Lab (ZLAB)?
What is the market cap of Zai Lab (ZLAB)?
